Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$413K Buy
6,581
+748
+13% +$52.1K 0.02% 629
2025
Q4
$387K Buy
5,833
+2,793
+92% +$181K 0.02% 646
2025
Q3
$205K Sell
3,040
-440
-13% -$34.8K 0.01% 777
2025
Q2
$304K Sell
3,480
-1,468
-30% -$115K 0.02% 541
2025
Q1
$338K Buy
4,948
+2
+0% +$163 0.03% 390
2024
Q4
$385K Buy
4,946
+1,663
+51% +$123K 0.03% 343
2024
Q3
$220K Sell
3,283
-1,605
-33% -$132K 0.02% 424
2024
Q2
$554K Buy
4,888
+112
+2% +$14.2K 0.05% 243
2024
Q1
$662K Sell
4,776
-4,322
-48% -$543K 0.06% 219
2023
Q4
$1.13M Buy
9,098
+4,950
+119% +$506K 0.05% 238
2023
Q3
$387K Buy
+4,148
New +$468K 0.05% 227

Other funds holding DXCM

Syon Capital's DXCM Position: Q1 2026 in Review

Syon Capital increased its DexCom (DXCM) stake by 13% in Q1 2026, buying an estimated $52.1K and bringing the position to 6,581 shares worth $413K. The position accounts for 0.02% of the portfolio, ranked #629.

Syon Capital first reported a position in DXCM in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.13M in Q4 2023. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Syon Capital held 6,581 shares of DexCom worth $413K as of Q1 2026.
  • Syon Capital bought 748 DexCom shares in Q1 2026, an estimated $52.1K.
  • DexCom made up 0.02% of Syon Capital's portfolio in Q1 2026, its #629 holding.
  • Syon Capital first reported a position in DexCom in Q3 2023 and has held it in 11 quarters since.
  • Syon Capital's DexCom position peaked at $1.13M in Q4 2023.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Syon Capital's 13F filing for Q1 2026, filed 13 May 2026.